Merck
 
4Q Revenues: $10.1 billion (-1%)

4Q Earnings: $1.2 billion (+21%)

FY Revenues: $39.8 billion (+1%)

FY Earnings: $5.7 billion (+28%)

Comments: KEYTRUDA sales were up 148% to $1.4 billion for the year driven by new indications and new markets. JANUVIA/JANUMET sales were $6.1 billion, up 2% for the year. ZETIA/VYTORIN sales were down 2% to $3.7 billion. GARDASIL/GARDASIL 9 sales were up 14% to $2.2 billion due to increased pricing and demand in the U.S. PROQUAD, M-M-R II and VARIVAX sales were up 9% to $1.6 billion. ISENTRESS sales were down 6% to $1.4 billion for the year. REMICADE sales declined 29% to $1.3 billion due to biosimilar competition in Europe. CUBICIN sales were down 4% to $1.1 billion. SINGULAIR sales were down 4% to $915 million. PNEUMOVAX 23 sales were up 18% to $641 million due to the adoption of recently issued vaccination guidelines from the CDC. Animal Health sales were up 4% to $3.5 billion for the year. 4Q and FY15 results included a $680 million charge related to the settlement of VIOXX shareholder class action litigation.